{"classes":[{"categories":[{"measurements":[{"comment":"Insufficient number of participants with events","groupId":"OG000","lowerLimit":"47.34","upperLimit":"NA","value":"73.72"},{"comment":"Insufficient number of participants with events","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"179"},{"groupId":"OG001","value":"179"}],"units":"Participants"}],"description":"Overall survival (OS) is defined as the time between the date of randomization and the date of death. OS will be censored on the last date a participant was known to be alive.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants receive investigator-choice of platinum doublet chemotherapy regimens in 3-week cycles up to a maximum of 3 cycles of IV chemotherapy (ie, 9 weeks of treatment; each cycle is 21 days).\n\nFollowing definitive surgery, participants could receive up to 4 cycles of adjuvant chemotherapy and/or radiation at the discretion of the investigator.","id":"OG000","title":"Arm B: Platinum Doublet Chemo"},{"description":"Participants receive nivolumab 360 mg IV + platinum doublet chemotherapy in 3-week cycles up to a maximum of 3 cycles of IV chemotherapy (ie, 9 weeks of treatment; each cycle is 21 days).\n\nFollowing definitive surgery, participants could receive up to 4 cycles of adjuvant chemotherapy and/or radiation at the discretion of the investigator.","id":"OG001","title":"Arm C: Nivo 360 mg + Platinum Doublet Chemo"}],"paramType":"MEDIAN","populationDescription":"All concurrently randomized participants in Arm C and Arm B","reportingStatus":"POSTED","timeFrame":"From randomization to the date of death (Up to approximately 93 months)","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}